PT - JOURNAL ARTICLE AU - Yaser Elkelhy AU - Samer Eid AU - M.M. Omar AU - Tarek Salah TI - Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer AID - 10.1183/13993003.congress-2015.OA271 DP - 2015 Sep 01 TA - European Respiratory Journal PG - OA271 VI - 46 IP - suppl 59 4099 - http://erj.ersjournals.com/content/46/suppl_59/OA271.short 4100 - http://erj.ersjournals.com/content/46/suppl_59/OA271.full SO - Eur Respir J2015 Sep 01; 46 AB - Background: Oral form of vinorelbine is a convenient way to provide a consolidation treatment to patients with achieved response or stable disease. We studied its value in inoperable stage III non-small cell lung cancer (NSCLC)Methodology: radiotherapy began in week 1. cisplatin IV (20mg/m2) was given over 2 hours on days 1-4 & vinorelbine ditartrate IV (15mg/m2) over 5-10 minutes on days 1&8 for 2 courses concurrently with radiotherapy 5 days a week for 6 weeks, fractionated dose of 60Gy/30 fraction external beam radiotherapy. In absence of disease progression or unacceptable toxicity with still unresectable localised NSCLC following concurrent chemoradiation, consolidation therapy with oral vinorelbine at 80mg/m2 weekly is initiated for up to 12 weeks.Results: 56 patients were enrolled. 8.7% of 46 patients were resectable, 1 achieved a complete pathological response (PCR in 2%), 65.2% partial response, 17% stable disease and 8.7% progressive disease. Median duration of response was 6 months. Median progression free-survival was 4.8 months. Median overall survival time was 10 months and the 1 year survival was 42.6%. Main toxicities were: Grade 3&4 neutropenia observed in 32%; Nausea, vomiting, diarrhea were the major nonhematological toxicitiesConclusion: we suggest consolidation therapy with vinorelbine may probably prolong the efficacy of the combination regimen. The convenience offered to patients by an oral form of vinorelbine is a definite asset for consolidation therapy as most studies of maintenance therapy are on advanced disease. Further studies are needed to confirm its efficacy.